EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Predicting Visual Acuity Responses to Anti-VEGF Treatment in the Comparison of Age-related Macular Degeneration Treatments Trials Using Machine Learning

Rajat S Chandra, Gui-Shuang Ying

Ophthalmology Retina · 2024-05 · 8 (5) · 419-430

DOI: 10.1016/j.oret.2023.11.010 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Retina, 2024-05. Verfasst von Rajat S Chandra und 1 weiteren Autor:innen. Beteiligte Einrichtung: Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Hauptthemen laut MEDLINE: Visual Acuity, Machine Learning, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, Research to Prevent Blindness, National Eye Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate multiple machine learning (ML) models for predicting 2-year visual acuity (VA) responses to anti-vascular endothelial growth factor (anti-VEGF) treatment in the Comparison of Age-related Macular Degeneration (AMD) Treatments Trials (CATT) for patients with neovascular AMD (nAMD). DESIGN: Secondary analysis of public data from a randomized clinical trial. PARTICIPANTS: A total of 1029 CATT participants who completed 2 years of follow-up with untreated active nAMD and baseline VA between 20/25 and 20/320 in the study eye. METHODS: Five ML models (support vector machine, random forest, extreme gradient boosting, multilayer perceptron neural network, and lasso) were applied to clinical and image data from baseline and weeks 4, 8, and 12 for predicting 4 VA outcomes (≥ 15-letter VA gain, ≥ 15-letter VA loss, VA change from baseline, and actual VA) at 2 years. The CATT data from 1029 participants were randomly split for training (n = 717), from which the models were trained using 10-fold cross-validation, and for final validation on a test data set (n = 312). MAIN OUTCOME MEASURES: Performances of ML models were assessed by R2 and mean absolute error (MAE) for predicting VA change from baseline and actual VA at 2 years, by the area under the receiver operating characteristic curve (AUC) for predicting ≥ 15-letter VA gain and loss from baseline. RESULTS: Using training data up to week 12, the ML models from cross-validation achieved mean R2 of 0.24 to 0.29 (MAE = 9.1-9.8 letters) for predicting VA change and 0.37 to 0.41 (MAE = 9.3-10.2 letters) for predicting actual VA at 2 years. The mean AUCs for predicting ≥ 15-letter VA gain and loss at 2 years was 0.84 to 0.85 and 0.58 to 0.73, respectively. In final validation on the test data set up to week 12, the models had an R2 of 0.33 to 0.38 (MAE = 8.9-9.9 letters) for predicting VA change, an R2 of 0.37 to 0.45 (MAE = 8.8-10.2 letters) for predicting actual VA at 2 years, and AUCs of 0.85 to 0.87 and 0.67 to 0.79 for predicting ≥ 15-letter VA gain and loss, respectively. CONCLUSIONS: Machine learning models have the potential to predict 2-year VA response to anti-VEGF treatment using clinical and imaging features from the loading dose phase, which can aid in decision-making around treatment protocols for patients with nAMD. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Visual AcuityMachine LearningAngiogenesis InhibitorsVascular Endothelial Growth Factor AIntravitreal InjectionsRanibizumabWet Macular DegenerationHumansMaleFemaleAgedFollow-Up StudiesTomography, Optical CoherenceBevacizumabTreatment OutcomeROC CurveAged, 80 and over

Stichwörter der Autor:innen

Age-related macular degenerationAnti-VEGF therapyMachine learningPredictionVisual acuity

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumabBevacizumab

Autor:innen und Institutionen

  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Department of Ophthalmology, Center for Preventive Ophthalmology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: gsying@pennmedicine.upenn.edu.

Förderung

  • NEI NIH HHS
  • Research to Prevent Blindness
  • National Eye Institute

Zitieren

APA

Chandra, R. S., & Ying, G. S. (2024). Predicting Visual Acuity Responses to Anti-VEGF Treatment in the Comparison of Age-related Macular Degeneration Treatments Trials Using Machine Learning. Ophthalmology Retina, 8(5), 419-430. https://doi.org/10.1016/j.oret.2023.11.010

Vancouver

Chandra RS, Ying GS. Predicting Visual Acuity Responses to Anti-VEGF Treatment in the Comparison of Age-related Macular Degeneration Treatments Trials Using Machine Learning. Ophthalmology Retina. 2024;8(5):419-430. doi:10.1016/j.oret.2023.11.010

BibTeX
@article{Chandra2024,
  author = {Chandra, Rajat S and Ying, Gui-Shuang},
  title = {Predicting Visual Acuity Responses to Anti-VEGF Treatment in the Comparison of Age-related Macular Degeneration Treatments Trials Using Machine Learning},
  journal = {Ophthalmology Retina},
  year = {2024},
  volume = {8},
  number = {5},
  pages = {419--430},
  doi = {10.1016/j.oret.2023.11.010}
}
Kostenlos starten →